NewsSource: Lin Shaonan GCP

EClinCloud: In the First Tier of AI for Clinical Trials

5 min readEClinCloud Editorial Team
Header image for the report on EClinCloud in the first tier of AI + clinical trials

This article is reprinted from the WeChat official account "Lin Shaonan GCP," published on April 16, 2026.

Why does it take ten years to develop a new drug?

It is not solely because the science is difficult.

A considerable portion of that time is spent on things like this: data entered incorrectly and re-entered; files left unarchived and filed retroactively; disconnected systems requiring manual data transfer; and reports generated only to wait in line for human review.

None of these tasks is difficult in itself; what makes them a problem is that they happen every day across thousands of clinical trials worldwide, quietly eating away at timelines.

EClinCloud has been asking the same question: Can these steps stop relying on manual work?

A Forward-Looking Judgment

Before large models entered the public eye—when AI was still a rarely heard term for most companies—EClinCloud made a judgment:

The clinical trial industry is undergoing an unprecedented foundational transformation.

The next phase is not "AI-assisted manual work," but a genuine transition from a "digital SaaS platform" to an "AI-native clinical trial company"—giving systems "memory" and "execution capability," redefining each stage with AI agents, and turning tasks once performed manually into AI-driven automated workflows.

It is not merely about providing software, but about reshaping clinical trials with AI—reducing the burden on pharmaceutical companies and accelerating progress for patients.

This judgment meant that simply layering AI onto existing software is not enough. The more fundamental question is: Is the data connected?

If data does not flow, no matter how smart the AI is, it is just putting a clever gatekeeper on a silo.

One thing EClinCloud spent a long time building is genuine data flow across systems including EDC, RTSM, CTMS, eTMF, eCOA, and IRC. Trial participant information, drug data, randomization, and imaging assessments are connected in real time, with a single account managing all systems.

Only when the data is complete does AI have complete "raw materials."

Then AI Begins to Enter Every Stage

From the moment a study starts: CTMS integrates AI during project initialization to automatically extract key protocol information, compressing startup workflows that previously required manual organization—improving project management efficiency by 70% and reducing risk by 50%.

In the execution phase, within EDC, AI-assisted study build saves an average of 5 to 20 work hours; data capture combining OCR and NLP improves entry efficiency by 30% and cuts manual review volume in half. In eCOA, AI models assist with clinical outcome assessment (COA), increasing patient compliance by 35% and achieving diagnostic assistance accuracy above 96%. In eTMF, document classification recommendation accuracy exceeds 95%, so document filing no longer requires manual page-by-page sorting.

At the data review stage, the BI risk early-warning system runs continuously in the background, scanning data quality in real time and automatically flagging anomalies. The old reactive model—waiting for reports to come out before discovering issues—gives way to a system that raises a yellow flag before problems emerge.

Finally, in analysis and regulatory submission, the BI decision-support module automatically generates statistical outputs and visual analytics, supporting dynamic dashboards and intelligent decision recommendations. Data analysis shifts from "post-hoc compilation" to "real-time insight."

These figures were all generated across multiple real-world projects.

Figure: EClinCloud 2026 User Conference poster—"AI Leading × A New Chapter Begins," May 13, 2026, Pudong, Shanghai. Scan the QR code to register; seating is limited.

In 2026, AI in clinical research is entering an intensive real-world deployment phase. On May 13, the EClinCloud 2026 User Conference will be held in Pudong, Shanghai, under the theme "AI Leading · A New Chapter Begins."

Professionals from pharmaceutical companies, CROs, and the AI field will sit down together—not to talk concepts, but to discuss real projects: how data flows, how evidence is generated, and what it takes to move AI from idea to implementation.

Held on the eve of the DIA Annual Meeting, the conference will feature event gifts and a dinner raffle, allowing attendees to take away their own Real AI Experience.

Something Harder Than Technology

There is one aspect of clinical trials that differs from every internet product.

When a piece of software has a bug, you fix it and push an update—at worst, users complain a little. But when something goes wrong with clinical trial data, it can affect the marketing authorization decision for a new drug, and it can affect real patients.

Regulatory standards from bodies such as the FDA, EMA, ICH, and CDISC exist not to make life difficult for companies, but because painful, costly lessons have occurred in real history.

That is also why many technology companies can build AI, yet struggle to truly break into the clinical trial space.

Compliance capability cannot be built in the short term simply by adding headcount; it is accumulated audit by audit, project by project, and year by year.

EClinCloud undergoes more than 10 external security audits each year; its data protection compliance covers major global regulatory frameworks, with no major findings to date.

This is not a number to boast about—it is the basic threshold for entry into this industry, and clearing that threshold is already difficult in itself.

On average, it takes ten years for a new drug to go from the laboratory to patients.

Within those ten years, how much time is necessary waiting and how much is avoidable overhead—EClinCloud is seriously working to answer that question.

In five years, it turned "AI reshaping clinical trials" from a judgment into a system that actually runs.

For the industry as a whole, the more players like this there are, the less time patients waiting for new drugs will have to wait.

Author bio: I am Lin Shaonan, an observer of AI + clinical trials. I have founded several AI clinical trial discussion groups, which currently have 4000+ members.

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.